Kane Biotech Welcomes Renowned Canadian Veterinarian, Dr. Jean Gauvin, as Chief Veterinary Officer

BioSpace | February 20, 2020

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the Kane Biotech R&D team’s Animal Health research and product development, and be the media voice of Kane Biotech’s Animal Health business unit. Dr. Gauvin will also serve as a member of Kane Biotech’s Scientific Advisory Board.

Spotlight

Trillions of microbes are living on and inside of you, and we’re only continuing to find out the role these organisms play in our health. A new report based on deliberations from 13 leading scientists from institutions such as Harvard, CalTech and the National Institutes of Health, details what we know about the microorganisms living inside of us.

Spotlight

Trillions of microbes are living on and inside of you, and we’re only continuing to find out the role these organisms play in our health. A new report based on deliberations from 13 leading scientists from institutions such as Harvard, CalTech and the National Institutes of Health, details what we know about the microorganisms living inside of us.

Related News

RESEARCH

TurtleTree and Solar Biotech enter strategic partnership

TurtleTree | August 16, 2021

Solar Biotech, led by industrial biotech expert Alex Berlin, has become a significant piece of the puzzle for sustainable food tech companies taking products to market. TurtleTree knew from the beginning that one of the biggest challenges for food tech companies was developing the technologies required to scale up bio-manufacturing processes. TurtleTree is a biotech company based in Singapore and the US. The company is focused on providing access to the best nutrients in milk using sustainable technologies. With so many food tech companies coming onto the scene, dedicated talent and resources needed to reach commercial scale are scarce. Microbes like yeast and fungi are nature's perfect tools for bio-manufacturing. Precision fermentation uses microbial hosts as cell factories to produce specific beneficial ingredients in a controlled environment without having to go through animal agriculture. What happens in the lab is just half the battle. Efficient precision fermentation and product recovery at an industrial scale demand agility, flexibility, decades of experience, unique multidisciplinary process and equipment engineering, and a well-connected network of bioprocessing and microbial biotech partners, all professionally taken care of by Solar Biotech. Many startups and VC's believe major breakthroughs in the lab will result in the real-world commercialization of bioproducts. The reality is that many projects run into years of roadblocks and scale-up challenges making commercial viability difficult. There is a major difference between traditional fermentation methods, where the microbial biomass itself is the end product, and precision fermentation, where a highly technical skillset is required to obtain the specific desired bioproduct synthesized by the microbial host. A key factor in reaching price parity with traditional food production methods is the availability of technologically advanced large-scale food-grade bioprocessing facilities, which combine precision fermentation and downstream processing lines that are customized for each player. Based on a Good Food Institute (GFI) report, available biomanufacturing facilities suitable for food precision fermentation is only 3% of the total manufacturing capacity. With the increasing demand for large-scale precision fermentation, we are already seeing the supply falling short. Alex Berlin, Solar Biotech Founder, CEO & CTO, having built his extensive experience from his time at Novozymes and other industrial biotech companies, has a track record of developing and scaling up bioproducts that were quite challenging for many others. The TurtleTree team identified this value early on, built a strong collaboration model, and made an investment in Solar Biotech. "TurtleTree's decision to back Alex Berlin and Solar Biotech's team from the early days has started to pay dividends. Our teams can focus on lab-scale R&D and go-to-market as we look to play a major role in the sustainable food supply chain, while Solar Biotech delivers the bioprocessing technologies required for production at scale," says Max Rye, co-founder and chief strategist of TurtleTree. "My team and I are passionate about not only producing the food of the future but also about making a difference in the way these bioproducts are made. Industrial Biomanufacturing at scale has not evolved significantly for decades. We are committed to making a difference, in particular, with a focus on the deployment of unique cutting edge and sustainable bioprocessing technologies. We believe solar energy and a circular economy strategy will play a major role in how we produce novel bio-processed ingredients," says Alex Berlin. About TurtleTree TurtleTree is unlocking access to the natural ingredients found in milk using a host of cell-based technologies. Together with its valued partners, TurtleTree is able to achieve resource efficiency and provide millions with access to the beneficial nutrients found in milk. We aim to transform performance nutrition, food systems, and cellular agriculture with our cell-based technology platform. About Solar Biotech Founded in 2019 by Alex Berlin, Solar Biotech brings bioproducts from benchtop to industrial bioprocessing commercial scale. Its proprietary technology uses a combination of unique technologies, skills, and experience to swiftly adapt to the needs of each bioproduct. Solar Biotech customises modular plant architectures, called BioNodes, for specific bioproducts. Solar Biotech's 100% solar-powered platform and facility help precision fermentation companies scale up their operations sustainably and at a fraction of the cost.

Read More

DIAGNOSTICS

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

Oxford BioTherapeutics | June 14, 2022

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen's linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discovery platform. The companies will support these R&D efforts through joint funding and by combining their respective proprietary technologies. "I am very enthusiastic about our new partnership with ImmunoGen, a leader in the development of ADCs," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. "The company's expertise, in combination with the unique targets from our OGAP® database, provides potential to strengthen our respective drug pipelines with novel and highly differentiated ADCs for cancer patients in need of novel therapeutic options." As part of the agreement, OBT will receive an upfront payment from ImmunoGen, reflecting OBT's preclinical programs to be included in the partnership. In addition, once antibodies generated by OBT have been coupled with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development programs to further develop on its own. Each company is eligible to receive milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones, as well as tiered royalties as a percentage of worldwide commercial sales, with respect to each program selected by the other company. Once a company has chosen a given program, it will be solely responsible for all R&D costs associated with the specific program. "OBT has demonstrated expertise in identifying novel targets for the development of specific antibodies – two key components to generating successful ADCs," said Stacy Coen, ImmunoGen's Senior Vice President and Chief Business Officer. "This expertise, combined with ImmunoGen's portfolio of cancer-killing payloads and linkers, will be instrumental as both companies work to develop novel ADCs designed to address cancers with high unmet need. We look forward to working with OBT as we expand and diversify our investment in ADC research capabilities, deepen our pipeline, and transition to a fully-integrated oncology company." ImmunoGen's portfolio is comprised of next-generation maytansinoid, DNA-acting, and novel camptothecin toxins and proprietary linkers. This collaboration will utilize novel targets identified by OBT combined with ImmunoGen's proprietary toxins and associated linkers. OBT has clinical experience with ImmunoGen's ADC platform and DM4 payload, which is utilized in OBT's lead program OBT076, an ADC currently in clinical trials as a monotherapy, as well as in combination with checkpoint inhibitors, in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian, and lung cancer. About Oxford BioTherapeutics Oxford BioTherapeutics is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA; with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. OBT's lead clinical program, OBT076, an ADC utilizing an Immunogen toxin, initiated expansion in a U.S. Clinical Trial in 2021 in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells correlates with adverse outcomes (lower progression free and overall survival), suggesting that this process contributes to the progression of several cancers.

Read More

MEDTECH

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Optimised synthetic routes are then used as input for RoboRXN, an automated platform for molecule synthesis. Arctoris has developed Ulysses, an end-to-end automated platform for drug discovery research. The platform ensures accuracy, precision, and reproducibility by leveraging robotic experiment execution and digital data capture technologies across cell and molecular biology and biochemistry/biophysics. Experiments conducted with Ulysses generate more than 100 times more datapoints per assay compared to industry standard, leading to deeper insights and accelerated progress compared to manual methods. The two platforms are now being combined for the first time in a research collaboration that will see new small molecule inhibitors for undisclosed targets being designed, made, tested, and analysed (DMTA) in an autonomous, closed loop approach. Concretely, IBM Research will design and synthesize novel chemical matter (Design, Make), to be profiled and evaluated by Arctoris (Test, Analyze), with the resulting data informing the subsequent iteration of the DMTA cycle. The collaboration is currently on-going; financial terms were not disclosed. About IBM Research For more than seven decades, IBM Research has defined the future of information technology with more than 3,000 researchers in 16 locations across five continents. Scientists from IBM Research have produced six Nobel Laureates, 10 U.S. National Medals of Technology, five U.S. National Medals of Science, six Turing Awards, 19 inductees in the National Academy of Sciences and 20 inductees into the U.S. National Inventors Hall of Fame. About Arctoris Arctoris is a biotechnology company founded and headquartered in Oxford with additional operations in Boston and Singapore. Ulysses, the unique technology platform developed by Arctoris, enables the company to conduct its R&D – from target via hit and lead to candidate – significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates richer, more reliable data, enabling better decisions both in human-driven and computational drug discovery, leading to higher success rates and an accelerated progression of programs towards the clinic. Led by an experienced team, Arctoris pursues its internal pipeline of small molecule inhibitors in different indications, and also partners with other biotech and pharma companies for small molecule and biologics discovery, with partners in the US, UK, Germany, Australia, Korea, China, and several other countries.

Read More